Journal of Biomedical Sciences | ISSN: 2960-9356
Research Article Peer-review, Open Access

Analysis of the Use of Tranquilizers, Side Effects and Disadvantages

Sokhib Rashidov Zamon o'g'li [1]

Rukhshonakhon Boboqulova Anvarbek qizi [2]

Muslimakhon Makhmudova Shukhratjon qizi [3]

Shakhzoda Ruzimurodova Shavkat qizi [4]

Abstract: BZDs exhibit a higher risk of dependence and misuse. Over time, excitatory glutamine receptors may become more sensitive in tandem with a desensitization of GABA's inhibitory activity. Because of this neuroadaptive mechanism, many long-term users require higher dosages for comparable results. The sympathetic nervous system, potential seizures, and symptoms that are often the reverse of the intended therapeutic impact occur when the medication concentration in blood and tissue decreases. Due to their susceptibility to the effects of BZD, the elderly, children, pregnant women, and their newborns are the four primary populations that should be most concerned about this. Additionally, one study found that individuals prescribed BZD had a twofold increased chance of dying when compared to controls. Patients with schizophrenia on antipsychotic treatment frequently have sedative side effects, which have an impact on treatment compliance and the patients' quality of life. Strong data demonstrating the start and resolution of sedation is still lacking, despite the belief that tolerance to sedation develops. We sought to close this gap by evaluating the dynamics of sedation onset and resolution in individuals with schizophrenia using different antipsychotics. Clonazepam tapering is now used to treat withdrawal, whereas flumazenil should be used to address overdose. Few medications have been shown to be effective in randomized control trials when tried as a withdrawal treatment. There is space in the body of research for more investigation into non-BZD alternative approaches to withdrawal treatment.

Keywords: Clonazepam, benzodiazepines, GABA, withdrawal, cognitive decline, sedative side effects.

[1,2,3,4] Department of Pharmacology of the Tashkent State Medical University

Introduction. One percent of people worldwide suffer with schizophrenia, making it a common illness. The main pharmacological treatment for individuals with schizophrenia is antipsychotics, which are frequently required to control symptoms and avoid recurrence. Antipsychotic use over time is linked to a decreased death rate. Antipsychotics, however, have a number of adverse effects, such as drowsiness,

hyperprolactinemia, metabolic and cardiovascular problems, and sexual dysfunction. These adverse effects may lower adherence, lower the user's quality of life, and ultimately raise the chance of relapse. Some of the most frequent side effects of antipsychotic medication include sedation, somnolence, weariness, and drowsiness. These side effects significantly interfere with day-to-day activities [1,2,3]. According to Hynes and colleagues, 75% of schizophrenia inpatients claimed that antipsychotics caused them to feel sleepy every day. There is no conclusive evidence regarding the typical start and end times of sedation following the initiation of antipsychotic treatment, despite its high frequency and significant impact on patient wellbeing. The temporal dynamics of this process are yet unknown, even though patients may eventually gain tolerance. Clinical decisions are made more difficult by this ambiguity, particularly when it comes to therapy modifications brought on by sedation or additional diagnostic testing for less frequent causes of chronic drowsiness. Different receptor profiles of antipsychotic drugs are linked to different chances of sedative side effects. The risk of sedation differs among antipsychotics, according to a thorough meta-analysis. One of the primary causes of sedation is antipsychotics' affinity for the histamine H1 receptor. Nonetheless, some research has linked sedation to the adrenergic α1 receptor and muscarinic M1 and M4 receptors, suggesting that the effects of antipsychotics on different receptors are complicated. There have also been reports of sex differences in antipsychotic medication tolerability, particularly fatigue. Age, weight, and drug formulations (such as oral and long-acting injectable [LAI]) are linked to variations in pharmacokinetics and may affect the likelihood of side effects [4,5,6,7]. Compared to oral medications, LAIs may often have less adverse effects. In order to ascertain the temporal trajectory of sedative adverse events brought on by antipsychotic medication in patients with schizophrenia and schizoaffective disorder, including the time to onset and remission of sedation, this meta-analysis used individual participant data (IPD). Furthermore, it did not thoroughly examine the impact of significant confounders including sex, age, and weight. Meta-analyses of individual participant data on antipsychotic-induced sedation trajectories were not found. By providing an analysis of the onset and resolution of sedation across antipsychotics using individual participant data from randomized placebo-controlled trials, our study seeks to close this gap by evaluating the impact of patient characteristics and drug-specific factors on clinical decision making [8,9,10,11]. The drug class's long-term users frequently show signs of dependence and are at a significant risk of abuse. This should give people a break because stopping BZD after long-term use causes withdrawal symptoms and puts heavy users at risk for seizures. Short-acting BZDs typically show increased reliance and seem to carry a greater risk of negative consequences upon sudden withdrawal. The rate and intensity of hypnotic withdrawal are determined by a number of factors. These include: (1) the length of usage; (2) the elimination half-life (long-acting or short-acting); (3) the daily dosage; (4) the taper rate; and (5) the BZD's efficacy. According to one study, those who stopped taking long-acting BZDs suddenly after six or more months had a withdrawal rate of about 40%. Because BZDs might lower the seizure threshold, cause gait instability, and impair balance, it is especially important to use caution while using them in the elderly. Nowadays, more people are seeking therapy for issues associated with BZD usage dependency. Thus, the purpose of this review is to highlight the indications for using BZD, the risks of withdrawing from BZD, worries about the cognitive decline linked to BZD use, and the clinical research on this cognitive decline and the management of withdrawal symptoms [12-16].

The main purpose of this brief review is to analyze the use, side effects and disadvantages of tranquilizers based on the results of reputable scientific studies.

The study's added value. The temporal trajectory of sedative adverse events linked to antipsychotic medication in patients with schizophrenia and schizoaffective disorder is examined in this study, which is the first meta-analysis based on individual participant data. According to our research, sedation usually starts in the first few days of therapy, with roughly 80% of occurrences taking place in the first two weeks. About 25% of patients had sedation that lasted longer than four weeks, while 50% of instances cleared in a week. This work offers vital insights into the dynamics of sedative effects and emphasizes the significance of variables such drug formulation, receptor profiles, and patient demographics by methodically assessing the duration to onset and resolution of sedation across distinct antipsychotics [1-

5]. These results give medical professionals evidence-based information to better predict and handle sedative side effects. ***Consequences of all the information at hand.*** The results of this meta-analysis have significant ramifications for how sedation is managed in the treatment of schizophrenia. This study aids in clinical decision-making regarding treatment modifications and the necessity of additional diagnostic assessments when persistent sedation is noted by analyzing the temporal patterns of sedative adverse events. Clinicians can better manage expectations and educate patients on the likely course of sedation, which may improve adherence and lower early discontinuation, since the majority of sedative events occur in the first two weeks and resolve in half of the patients within one week. About 25% of patients continue to experience sedation after four weeks, which indicates the need for close observation and potential therapy modifications. The study can also offer recommendations on how patient attributes like weight, age, and sex, together with the particular antipsychotic medication administered, affect sedation risk. Future clinical studies can use the knowledge gathered from this study to improve treatment plans and improve the quality of life for individuals receiving antipsychotic therapy [6-12].

Benzodiazepine Indications. In terms of their indications for anxiety, BZDs are most frequently used for panic disorder and generalized anxiety disorder (GAD). In particular, diazepam is frequently used for anxiety, muscle spasms, and rectal seizures; temazepam is frequently used for insomnia; clonazepam is frequently used for anxiety and seizures; and lorazepam is frequently used for catatonia and seizure abortion when given intramuscularly or intravascularly. while it comes to anxiety, BZDs are utilized either as an abortive treatment for panic attacks or as a bridge while beginning another medicine. Antidepressants and SSRIs have become standard treatments for these disorders due to worries about withdrawal and usage dependency. However, BZDs are still frequently prescribed for these conditions due to their delayed start of effect [3-8]. The treatment of catatonia, seizure disorders, and alcohol and BZD withdrawal are other significant indications for the usage of BZDs. Catatonia, which is characterized by postural rigidity, immobility, purposeless activity, and disruptions in consciousness, is mostly treated with this family of drugs. People with schizophrenia, bipolar disorder, or a number of other illnesses may experience catatonia. Together with electroconvulsive therapy, BZDs are the primary treatment for catatonia because they have anxiolytic and sedative effects on the central nervous system. Additionally, BZDs are useful in acute seizures, cluster seizures, status epilepticus, and seizures brought on by alcohol and BZD withdrawal. Abortion with BZDs or other CNS sedatives is recommended since neuronal harm may start as soon as five minutes of seizure activity. Additionally, long-acting BZDs are used to gradually reduce and eventually stop the use of short-acting, chronic BZDs. Abruptly stopping BZDs' sedative effect on GABA results in hyperstimulation of the autonomic nervous system, which has symptoms and indicators that are similar to those of alcohol. Mainstay therapy includes long-acting BZDs to avoid BZD withdrawal seizures [11-15].

Treatment Duration. BZDs are quite successful in treating the disorders for which they are prescribed. However, recommendations for suggested usage are limited to a few weeks because to the serious risk of dependence and fatal withdrawal symptoms. Despite this, a number of studies show that many users continue to use the product for months, years, or even decades. Furthermore, a number of studies show that BZD use rises with age, with long-term use most common in those 65 and older. Two or more months at a therapeutic dose is considered long-term usage, and BZDs may have negative side effects. The elderly are particularly vulnerable to psychomotor impairment, auto accidents, and cognitive impairment, including impaired short-term memory, increased forgetfulness, and anterograde amnesia. Between 1% and 20% of users experience various side effects that are concerning, such as aggressive conduct and expressing displeasure towards others. The development of tolerance, which makes users require higher dosages to achieve the same level of symptom alleviation, is the primary cause of dependence [13-16].

Benzodiazepine Side Effects. The adverse effect profiles of BZDs are numerous and noteworthy. Passaro et al. reported an increased risk of falls in elderly hospitalized patients prescribed short-acting BZD. Premature birth and low birth weight are risks for mothers who use BZD during pregnancy.

Patients over 80 years of age have a significantly higher risk of falls resulting in injuries than patients under 80. Although the study revealed some teratogenic effects of BZDs on fetuses, the results are not statistically significant, and some of the abnormalities observed in the fetuses may have resulted from the use of other drugs, such as antidepressants. The risk for addiction is one of the crippling negative effects of BZDs [3,7,8]. The rate at which they are prescribed has increased due to their relative safety when compared to other depressants or barbiturates. Because BZD dependence typically results in withdrawal symptoms, the medication must be carefully tapered off when prescribed. A review of the literature examining the connection between BZD and suicide risk found that while BZD is frequently used to treat anxiety and insomnia, it can also raise the risk of suicide. Several studies in the literature have also suggested that BZD use is linked to an increased risk of suicide in its users. Alprazolam usage and cessation within two weeks interfere with the beginning and quality of sleep, raising the risk of suicide [10-16].

Discussion. To the best of our knowledge, this is the first IPD meta-analysis that thoroughly examines the course of sedative adverse events linked to antipsychotics and placebo in individuals with schizophrenia and schizoaffective disorder. We evaluated the dynamics of sedation by analyzing 19 placebo-controlled RCTs with 6791 participants. About 80% of cases occurred in the first two weeks following treatment commencement, and we discovered that the onset of sedation peaked in the first few days of treatment initiation. Approximately 75% of the sedation episodes resolved after a maximum of one month, and about half resolved within a week after commencement. According to our current research, tolerance to sedative side effects during antipsychotic treatment develops quickly [1,2,3]. Patients undergoing antipsychotic medication for schizophrenia frequently experience sedative side effects, such as weariness, somnolence, and drowsiness, which have a detrimental impact on treatment adherence and quality of life. The time trajectory of these episodes, including their start and remission, across various antipsychotic medications, however, is poorly understood. Few research included thorough evaluations of the temporal course of sedation, despite the fact that many described its prevalence as a common adverse event. Insights into the dynamic changes in sedation over time were limited since the existing research frequently concentrated on only two timepoints: the beginning and end of the observation period. One study examined the duration of sedation by combining data from seven randomized controlled trials on asenapine in patients with acute schizophrenia. However, the relatively small sample size and the emphasis on certain medications limited these findings. By concentrating on two critical timepoints—from treatment beginning to sedation onset and from sedation onset to its resolution—the study's primary goal was to examine the trajectory of sedation brought on by antipsychotics [4,11,12,14]. For every randomly assigned participant in the double-blind phase, the time of sedation onset and resolution was retrieved. The type and formulation (oral or LAI) of antipsychotics, together with demographic details like age, sex, and ethnicity, were also retrieved. The chosen terminology used by MedDRA to define sedative adverse effects were tiredness, somnolence, and sedation. Authors research sheds light on the dynamics of sedation linked to antipsychotics in a way that is therapeutically significant. Over 80% of sedative events occur during the first two weeks of antipsychotic medication, and tolerance to sedation develops rapidly. 50% of sedative episodes are cured after a week, regardless of the mode of administration (oral or LAI), however 24% of patients still experience drowsiness after four weeks. Our findings highlight the importance of closely monitoring patients in the early stages of treatment and indicate that if sedation lasts longer than a month, factors other than the antipsychotic itself should be taken into account. In addition to potentially improving patient care and lowering early treatment termination due to drowsiness, our study provides helpful guidelines for managing sedative side events during antipsychotic medication [3,8,9,10]. Clonazepam tapering is currently used to treat withdrawal, and flumazenil should be used to address overdose. Few medications have been shown to be effective in randomized control trials when tried as withdrawal treatments. There is space in the body of research for more investigation into withdrawal treatment approaches other than the BZD itself [15,16].

Conclusions. In the US, BZDs are among the most commonly prescribed medication classes. Anxiety, epilepsy and other seizure disorders, spasticity from CNS disease, catatonia, sleep disorders like insomnia, and withdrawal from alcohol and other BZDs are all treated with them right away. Chronic BZD use has been associated with violent behavior and expressive rage in a subgroup of users, as well as a decline in cognitive function, an increased risk of dementia and dementia-like disorders, and impaired sensory and motor function in the elderly.

The study's primary goal was to examine the course of antipsychotic-induced sedation by concentrating on two critical timepoints: from the start of therapy until the onset of drowsiness and from the onset of sedation to its resolution. In the double-blind phase, the onset and resolution times of sedation were retrieved for each randomly assigned subject. Along with the type and formulation (oral or LAI) of antipsychotics, demographic details like age, sex, and ethnicity were also retrieved. The chosen terms from MedDRA—sedation, somnolence, and fatigue—were used to define sedative adverse effects. Some of the lowest level phrases, such fatigue and drowsiness, are included in these three favored terms.

Authors considered several preferred term events that overlapped in time as a single event, with the onset date being marked by the first event and the end date by the resolution of the last event. Regardless of the severity or whether the events were connected to the interventions carried out in each research, we only included the initial sedation event that occurred during the double-blind phase. Day 1 was used as the start date of the intervention for creating the dataset.

References.

1. Nomura, Nobuyuki et al. The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomised, placebo-controlled, clinical trials in acute phase schizophrenia. The Lancet Psychiatry, Volume 12, Issue 4, 266 – 275.
2. Edinoff AN, Nix CA, Hollier J, Sagrera CE, Delacroix BM, Abubakar T, Cornett EM, Kaye AM, Kaye AD. Benzodiazepines: Uses, Dangers, and Clinical Considerations. Neurology International. 2021; 13(4):594-607. https://doi.org/10.3390/neurolint13040059
3. Fluyau, D.; Revadigar, N.; Manobianco, B.E. Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther. Adv. Psychopharmacol. 2018, 8, 147–168.
4. Balon, R.; Starcevic, V.; Silberman, E.; Cosci, F.; Dubovsky, S.; Fava, G.A.; Nardi, A.E.; Rickels, K.; Salzman, C.; Shader, R.I.; et al. The rise and fall and rise of benzodiazepines: A return of the stigmatized and repressed. Braz. J. Psychiatry 2020, 42, 243–244.
5. Quagliato, L.A.; Freire, R.C.; Nardi, A.E. Risks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines. Expert Opin. Drug Saf. 2018, 17, 315–324.
6. Votaw, V.R.; Geyer, R.; Rieselbach, M.M.; McHugh, R.K. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend. 2019, 200, 95–114.
7. McHugh, R.K.; Geyer, R.B.; Chase, A.R.; Griffin, M.L.; Bogunovic, O.; Weiss, R.D. Sex differences in benzodiazepine misuse among adults with substance use disorders. Addict. Behav. 2021, 112, 106608.
8. Cook, B.; Creedon, T.; Wang, Y.; Lu, C.; Carson, N.; Jules, P.; Lee, E.; Alegría, M. Examining racial/ethnic differences in patterns of benzodiazepine prescription and misuse. Drug Alcohol Depend. 2018, 187, 29–34.
9. Hernandez, N.M.; Cunningham, D.J.; Hinton, Z.W.; Wu, C.J.; Seyler, T.M. Are Patients Taking Benzodiazepines at Increased Risk for Complications Following Primary Total Knee Arthroplasty? J. Arthroplast. 2021, 36, 1611–1616.

10. Landolt, S.; Rosemann, T.; Blozik, E.; Brüngger, B.; Huber, C.A. Benzodiazepine and Z-Drug Use in Switzerland: Prevalence, Prescription Patterns and Association with Adverse Healthcare Outcomes. Neuropsychiatr. Dis. Treat. 2021, 17, 1021.
11. Abrahamsson, T.; Berge, J.; Öjehagen, A.; Håkansson, A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment—A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017, 174, 58–64.
12. Ait-Daoud, N.; Hamby, A.S.; Sharma, S.; Blevins, D. A Review of Alprazolam Use, Misuse, and Withdrawal. J. Addict. Med. 2018, 12, 4–10.
13. Reeves, R.R.; Kamal, A. Complicated withdrawal phenomena during benzodiazepine cessation in older adults. J. Am. Osteopath. Assoc. 2019, 119, 327–331.
14. Nafti, M.; Sirois, C.; Kröger, E.; Carmichael, P.-H.; Laurin, D. Is Benzodiazepine Use Associated with the Risk of Dementia and Cognitive Impairment-Not Dementia in Older Persons? The Canadian Study of Health and Aging. Ann. Pharmacother. 2020, 54, 219–225.
15. Dyer, A.H.; Murphy, C.; Lawlor, B.; Kennelly, S.P. NILVAD Study Group Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living with Mild to Moderate Alzheimer's Disease: Results From NILVAD. J. Am. Med. Dir. Assoc. 2020, 21, 194–200.
16. Pirker-Kees, A.; Dal-Bianco, P.; Schmidt, R. Effects of Psychotropic Medication on Cognition, Caregiver Burden, and Neuropsychiatric Symptoms in Alzheimer's Disease over 12 Months: Results from a Prospective Registry of Dementia in Austria (PRODEM). J. Alzheimers Dis. JAD 2019, 71, 623–630.